Juan Antonio García-Carmona
Neurologist at Santa Lucía General Hospital in Cartagena, associate professor of Pharmacology at the Catholic University of Murcia (UCAM), researcher in neuropsychiatry at the Murcian Institute for Bio-Health Research (IMIB)
This well-designed clinical trial (randomised, placebo-controlled and double-blind) suggests that a single dose of GH001, a synthetic inhaled formulation of mebufotenine (also known as 5-MeO-DMT), can produce a rapid and marked improvement in patients with treatment-resistant depression, with remission rates exceeding those of the placebo in just one week. The results are consistent with the growing body of evidence regarding fast-acting treatments in this field, particularly with similar substances, and point to a potential breakthrough in an area with few effective options.
However, the study has several significant limitations: it included a small number of patients and assessed outcomes over a very short period, making it difficult to determine whether the benefits are sustained in the long term. Furthermore, given that the treatment produces clear psychoactive effects, it is possible that patients and assessors could have guessed who was receiving it, which may have influenced the results. It should also be noted that the participants did not represent the most severe or chronic cases of treatment-resistant depression, and that many required further doses over time. Taken together, these factors mean the results must be interpreted with caution and confirmed in larger, longer-term studies.